Skip to main content
驱动力 logo

驱动力 — Investor Relations & Filings

Ticker · 920275 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 479 across all filing types
Latest filing 2023-08-27 Proxy Solicitation & In…
Country CN China
Listing Beijing Stock Exchange 920275

About 驱动力

https://www.chinaedrive.com/

Drive Power Bio-tech specializes in the research, development, and manufacturing of functional additives designed for animal nutrition. The company focuses on hematopoietic technology, providing solutions that enhance hemoglobin synthesis, strengthen immune responses, and support intestinal health. Its product portfolio includes specialized nutritional supplements that optimize metabolic processes and improve growth performance. By leveraging biotechnological innovation, the company develops high-efficiency additives aimed at enhancing physiological health and production efficiency in large-scale agricultural environments.

Recent filings

Filing Released Lang Actions
关于召开2023年第一次临时股东大会通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice announcing the convening of the 2023 first extraordinary general meeting of shareholders (临时股东大会通知公告). It details the meeting date, voting methods (including online voting), eligibility, agenda items for shareholder approval, registration methods, and contact information. It does not contain financial statements, audit results, or detailed management discussion. The document is relatively short (2109 characters) and serves as an announcement for the meeting rather than the meeting materials or results. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings, especially since it includes agenda items and voting instructions for the shareholders' meeting.
2023-08-27 Chinese
广东驱动力生物科技集团股份有限公司关于接待机构投资者调研情况的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement about a recent investor research meeting held on June 30, 2023, where the company responded to questions from institutional investors. It includes details about the meeting, participants, and Q&A on company products, market positioning, and future plans. The document is short (1177 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is not a full financial report, earnings release, or regulatory filing. It is an update on investor relations activities, specifically a summary of an investor research session. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-07-02 Chinese
广东驱动力生物科技集团股份有限公司股东增持股份计划公告
Major Shareholding Notification Classification · 95% confidence The document is a shareholder announcement regarding a plan by a significant shareholder and director to increase their shareholding in the company. It includes details about the shareholder's identity, the number of shares held before the increase, the planned increase amount, the method, period, and purpose of the increase, as well as risk warnings and compliance statements. There are no financial statements, earnings data, or management discussion of financial results. The document is a formal announcement of a shareholding increase plan by a major shareholder, which fits the definition of a Major Shareholding Notification (MRQ). The document length is short (1155 characters), and it is not an announcement of a report publication or a certification. Therefore, the correct classification is MRQ with high confidence.
2023-07-02 Chinese
大华会计师事务所（特殊普通合伙）关于对广东驱动力生物科技集团股份有限公司年报问询函的专项说明
Regulatory Filings
2023-06-19 Chinese
广东驱动力生物科技集团股份有限公司关于对北京证券交易所的年报问询函回复的公告
Annual Report Classification · 95% confidence The document is a detailed response to an inquiry from the Beijing Stock Exchange Listing Company Management Department regarding the company's annual report for the fiscal year 2022. It includes comprehensive financial data such as revenue, cost, gross profit margin by product category and region, customer concentration, accounts receivable, supplier information, and audit procedures. The presence of detailed financial tables, management explanations, and auditor's verification indicates this is part of the annual report or a detailed annual financial disclosure. The document is lengthy (15,000 characters) and contains substantive financial data and analysis, not merely an announcement or certification. Therefore, it fits the definition of an Annual Report (10-K). FY 2022
2023-06-19 Chinese
广东驱动力生物科技集团股份有限公司关于延期回复北京证券交易所问询函的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (723 characters) from Guangdong Driving Force Biotechnology Group Co., Ltd. It references receiving an inquiry letter (问询函) from the Beijing Stock Exchange's Listed Company Management Department regarding the company's annual report. The company states it is preparing a written response and requests an extension to submit the reply. There is no actual financial data or report content included, only a regulatory inquiry and response timeline. The document is an official regulatory announcement related to compliance and information disclosure obligations, not the annual report itself or a detailed financial report. Therefore, it fits best under Regulatory Filings (RNS).
2023-06-12 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.